Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response

Hepatology

Volumn 60, Issue 4, 2014, Pages 1187-1195

  Bichoupan, Kian ^a   Martel Laferriere, Valerie ^a   Sachs, David ^a   Ng, Michel ^a   Schonfeld, Emily A ^a   Pappas, Alexis ^a   Crismale, James ^a   Stivala, Alicia ^a   Khaitova, Viktoriya ^a   Gardenier, Donald ^a   Linderman, Michael ^a   Perumalswami, Ponni V ^a   Schiano, Thomas D ^a   Odin, Joseph A ^a   Liu, Lawrence ^a   Moskowitz, Alan J ^a   Dieterich, Douglas T ^a   Branch, Andrea D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ERYTHROPOIETIN; FILGRASTIM; HEMOGLOBIN; INTERFERON; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; COHORT ANALYSIS; CONTROLLED STUDY; COST OF ILLNESS; DRUG COST; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE COST; HEPATITIS C; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INTENTION TO TREAT ANALYSIS; LIMIT OF DETECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICAL RECORD REVIEW; MEDICARE; MIDDLE AGED; MIXED INFECTION; PRIORITY JOURNAL; REIMBURSEMENT; SCORING SYSTEM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; DRUG EFFECTS; ECONOMICS; HEPACIVIRUS; PHYSIOLOGY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; COST OF ILLNESS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 84927760966     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27340     Document Type: Article

References (53)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
2. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011;31:1090-1101.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
4. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293-300.
5. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-521, 521.e1-6.
6. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-338.
7. McCombs JS, Yuan Y, Shin J, Saab S. Economic burden associated with patients diagnosed with hepatitis C. Clin Ther 2011;33:1268-1280.
8. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011;17:531-546.
9. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011;45:e17-e24.
10. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012;143:608-618.e1-5.
11. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013;57:2164-2170.
12. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593-602.
13. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8:280-288, 288.e1.
14. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
15. Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004;39:333-342.
16. Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010;51:2069-2076.
17. Koh C, Heller T, Haynes-Williams V, Hara K, Zhao X, Feld JJ, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther 2013;37:887-894.
18. Martinez SM, Foucher J, Combis JM, Metivier S, Brunetto M, Capron D, et al. Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. PLoS One 2012;7:e47715.
19. Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol 2013;58:1104-1112.
20. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
21. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
22. Jonk YC, Adeniyi T, Knott A, Dieperink MD, Ho SB. Interferon-based therapies for hepatitis C: utilization, costs, and outcomes. Am J Pharm Benefits 2012;5:25-33.
23. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
24. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-1024.
25. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
26. Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, et al.; WEF Study Group. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol 2013;59:658-666.
27. Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, et al. Cost-Effectiveness analysis of direct-acting antiviral therapy for treatment-naive patients with chronic hepatitis C genotype 1 infection in the Veterans Health Administration. Clin Gastroenterol Hepatol 2013;11:1503-1510.
28. Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Appl Health Econ Health Policy 2013;11:65-78.
29. Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ 2014;17:65-76.
30. Blazquez-Perez A, San Miguel R, Mar J. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. Pharmacoeconomics 2013;31:919-931.
31. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al.; CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013;59:434-441.
32. U.S. Food and Drug Administration (FDA). Incivek (telaprevir) in combination with drugs peginterferon alfa and ribavirin (Incivek combination treatment): drug safety communication-serious skin reactions. Rockville, MD: U.S. Food and Drug Administration; 2012.
33. Holmes J, Thompson A, Bell S. Hepatitis C-an update. Aust Fam Physician 2013;42:452-456.
34. van der Meer AJ, Wedemeyer H, Feld JJ, Hansen BE, Manns MP, Zeuzem S, Janssen HL. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? J Hepatol 2014;60:191-196.
35. Holmberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, et al. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis 2013;57:240-246.
36. Mummadi RR, Petersen JR, Xiao SY, Snyder N. Role of simple biomarkers in predicting fibrosis progression in HCV infection. World J Gastroenterol 2010;16:5710-5715.
37. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-1325.
38. HCUP Databases. Healthcare Cost and Utilization Project. 2006-2011. Rockville, MD: Agency for Healthcare Research and Quality. http://www.hcup-us.ahrq.gov/databases.jsp. Accessed on October 30, 2013.
39. Camma C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012;56:850-860.
40. Thorlund K, Druyts E, El Khoury AC, Mills EJ. Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection. Clinicoecon Outcomes Res 2012;4:349-359.
41. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
42. Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol 2014;60:691-698.
43. Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat 2013;20:847-857.
44. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014;60:530-537.
45. Yang Z, Zhuang L, Yang L, Liu C, Lu Y, Xu Q, et al. Efficacy and safety of peginterferon plus ribavirin for patients aged >/= 65 years with chronic hepatitis C: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2013 Oct 28. pii: S2210-7401(13)00187-3. doi: 10.1016/j.clinre.2013.08.013. [Epub ahead of print].
46. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Aliment Pharmacol Ther 2012;36:91-103.
47. Rangnekar AS, Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther 2012;36:104-114.
48. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459.
49. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-2848.
50. Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis 2012;12:86.
51. Sethi N, Vong A, Firdoos S, Rourke M, Afdhal NH. Cost effectiveness of HCV triple therapy with protease inhibitors; the true cost of SVR. In: 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington DC, November 1-5, 2013.
52. Hezode C, Fontaine H, Dufour JF, Dominique G, Larrey D, Zoulim F, et al. Efficacy and safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotics according to the age. Data from the CUPIC cohort (ANRS CO20). In: 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 1-5, 2013.
53. Di Bisceglie AM, Kuo A, Rustgi V, Sulkowski MS, Sterling RK, Stewart T, et al. Virologic outcomes and adherence to treatment algorithms in a longitudinal study of patients with chronic hepatitis C treated with boceprevir (BOC) or telaprevir (TVR) in the United States (HCV-TARGET). In: 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 1-5, 2013.